Q-omics provides the consensus-scored TRUB1 profile across patient tissues and cancer cell-line models. TRUB1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRUB1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, TRUB1 RNA expression shows 20,462 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where TRUB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRUB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRUB1 survival associations across molecular data types. TRUB1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRUB1 RNA expression–survival associations across cancer types. High TRUB1 expression shows unfavorable associations in UVM, SCLC, ACC and LIHC, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for TRUB1 RNA expression.
This table summarizes TRUB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TRUB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRUB1 shows lower tumor expression in THCA and higher tumor expression in BLCA, HNSC, LUAD, STAD and BRCA. The BLCA box plot shows higher TRUB1 RNA expression in tumor versus normal tissue (log2 FC = +0.612, t-test p < 0.001).
This table shows molecular features associated with TRUB1 in patient tissues and cancer cell lines. In patient samples, TRUB1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRUB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
